Ratings by Guggenheim (Michael Schmidt)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/27/2026 | BeOne Medicines | ONC | Maintain | Buy (N/A) |
|
Details | ||
| 2/23/2026 | Genmab A/S | GMAB | Maintain | Buy (N/A) |
|
Details | ||
| 2/6/2026 | Nanobiotix S.A | NBTX | Maintain | Buy (N/A) |
|
Details | ||
| 1/27/2026 | Erasca Inc | ERAS | Maintain | Buy (N/A) |
|
Details | ||
| 1/20/2026 | Revolution | RVMD | Maintain | Buy (N/A) |
|
Details | ||
| 1/8/2026 | Monte Rosa Therapeutics | GLUE | Maintain | Buy (N/A) |
|
Details | ||
| 11/14/2025 | Erasca Inc | ERAS | Maintain | Buy (N/A) |
|
Details | ||
| 11/13/2025 | Mersana | MRSN | Downgrade | Neutral (Buy) |
8.87 (29.08) |
227.85% | Details | |
| 11/12/2025 | ADC Therapeutics | ADCT | Maintain | Buy (N/A) |
|
Details | ||
| 11/7/2025 | Foghorn Therapeutics | FHTX | New Coverage | Buy (N/A) |
4.00 (5.78) |
44.5% | Details | |
| 9/30/2025 | Merus N.V. | MRUS | Downgrade | Neutral (Buy) |
68.89 (90.00) |
30.64% | Details | |
| 9/23/2025 | Genmab A/S | GMAB | Upgrade | Buy (Neutral) |
28.60 (27.06) |
-5.38% | Details | |
| 8/14/2025 | Mersana | MRSN | Maintain | Buy (N/A) |
|
Details | ||
| 8/12/2025 | Compass Therapeutics | CMPX | Maintain | Buy (N/A) |
|
Details | ||
| 8/6/2025 | BeOne Medicines | ONC | Maintain | Buy (N/A) |
|
Details | ||
| 6/13/2025 | ADC Therapeutics | ADCT | Maintain | Buy (N/A) |
|
Details | ||
| 6/3/2025 | Kymera Therapeutics | KYMR | Maintain | Buy (N/A) |
|
Details | ||
| 5/14/2025 | Erasca Inc | ERAS | Maintain | Buy (N/A) |
|
Details | ||
| 5/9/2025 | Compass Therapeutics | CMPX | Maintain | Buy (N/A) |
|
Details | ||
| 5/8/2025 | Revolution | RVMD | Maintain | Buy (N/A) |
|
Details | ||
| 4/28/2025 | Spring Works Therapeutics | SWTX | Downgrade | Neutral (Buy) |
44.72 (46.99) |
5.08% | Details | |
| 4/4/2025 | Nanobiotix S.A | NBTX | Maintain | Buy (N/A) |
|
Details | ||
| 3/31/2025 | ADC Therapeutics | ADCT | Maintain | Buy (N/A) |
|
Details | ||
| 3/26/2025 | Adaptimmune Therapeutics plc | ADAP | Maintain | Buy (N/A) |
|
Details | ||
| 3/24/2025 | Verastem | VSTM | Maintain | Buy (N/A) |
|
Details | ||
| 3/10/2025 | ArriVent BioPharma | AVBP | New Coverage | Buy (N/A) |
21.87 (23.43) |
7.13% | Details | |
| 2/24/2025 | Compass Therapeutics | CMPX | New Coverage | Buy (N/A) |
2.92 (5.51) |
88.7% | Details | |
| 2/21/2025 | Spring Works Therapeutics | SWTX | Maintain | Buy (N/A) |
|
Details | ||
| 1/30/2025 | Zentalis Pharmaceuticals | ZNTL | Maintain | Buy (N/A) |
|
Details | ||
| 1/10/2025 | IGM Biosciences | IGMS | Downgrade | Neutral (Buy) |
6.20 (1.27) |
-79.52% | Details | |
| 1/8/2025 | Spring Works Therapeutics | SWTX | Maintain | Buy (N/A) |
|
Details | ||
| 12/3/2024 | Revolution | RVMD | Maintain | Buy (N/A) |
|
Details | ||
| 11/15/2024 | Adaptimmune Therapeutics plc | ADAP | Maintain | Buy (N/A) |
|
Details | ||
| 11/15/2024 | Zentalis Pharmaceuticals | ZNTL | Maintain | Buy (N/A) |
|
Details | ||
| 10/7/2024 | Immunocore Holdings | IMCR | Downgrade | Neutral (Buy) |
31.11 (32.94) |
5.88% | Details | |
| 9/30/2024 | Verastem | VSTM | New Coverage | Buy (N/A) |
2.69 (6.38) |
137.17% | Details | |
| 8/28/2024 | Nanobiotix S.A | NBTX | New Coverage | Buy (N/A) |
5.29 (33.99) |
542.53% | Details | |
| 5/15/2024 | Bolt Biotherapeutics, Inc. | BOLT | Downgrade | Neutral (Buy) |
1.33 (4.30) |
223.31% | Details | |
| 3/28/2024 | ADC Therapeutics | ADCT | New Coverage | Buy (N/A) |
4.20 (4.11) |
-2.14% | Details | |
| 3/14/2024 | Immuneering Corporation | IMRX | Downgrade | Neutral (Buy) |
5.88 (5.33) |
-9.35% | Details | |
| 2/29/2024 | Mersana | MRSN | Upgrade | Buy (Neutral) |
4.27 (8.87) |
107.73% | Details | |
| 2/27/2024 | Spring Works Therapeutics | SWTX | Maintain | Buy (N/A) |
|
Details | ||
| 2/5/2024 | Spring Works Therapeutics | SWTX | New Coverage | Buy (N/A) |
46.16 (46.99) |
1.8% | Details | |
| 1/5/2024 | Allogene | ALLO | Downgrade | Neutral (Buy) |
3.39 (2.30) |
-32.15% | Details | |
| 12/1/2023 | Immunogen Inc. | IMGN | Downgrade | Neutral (Buy) |
16.06 (31.25) |
94.58% | Details | |
| 7/27/2023 | Mersana | MRSN | Downgrade | Neutral (Buy) |
3.91 (29.08) |
643.73% | Details | |
| 6/27/2023 | Adicet Bio Inc. | ACET | Downgrade | Neutral (Buy) |
4.66 (7.29) |
56.44% | Details | |
| 6/15/2023 | Mersana | MRSN | New Coverage | Buy (N/A) |
9.29 (29.08) |
213.02% | Details | |
| 3/30/2023 | Immunocore Holdings | IMCR | New Coverage | Buy (N/A) |
47.86 (32.94) |
-31.17% | Details | |
| 3/21/2023 | ORIC Pharamceuticals | ORIC | Upgrade | Buy (Neutral) |
4.49 (10.38) |
131.18% | Details | |
| 1/3/2023 | Kymera Therapeutics | KYMR | Maintain | Buy (N/A) |
|
Details | ||
| 1/3/2023 | Immuneering Corporation | IMRX | Maintain | Buy (N/A) |
|
Details | ||
| 1/3/2023 | Bolt Biotherapeutics, Inc. | BOLT | Maintain | Buy (N/A) |
|
Details | ||
| 1/3/2023 | BeiGene, Ltd. | BGNE | Maintain | Buy (N/A) |
|
Details | ||
| 1/3/2023 | Allogene | ALLO | Maintain | Buy (N/A) |
|
Details | ||
| 1/3/2023 | Adicet Bio Inc. | ACET | Maintain | Buy (N/A) |
|
Details | ||
| 1/3/2023 | Adaptimmune Therapeutics plc | ADAP | Upgrade | Buy (Neutral) |
1.46 (0.05) |
-96.58% | Details | |
| 1/3/2023 | Fate Therapeutics | FATE | Downgrade | Neutral (Buy) |
10.09 (1.33) |
-86.82% | Details | |
| 12/12/2022 | Erasca Inc | ERAS | Maintain | Buy (N/A) |
|
Details | ||
| 11/29/2022 | Seagen | SGEN | Maintain | Buy (N/A) |
|
Details | ||
| 11/11/2022 | Zentalis Pharmaceuticals | ZNTL | Maintain | Buy (N/A) |
|
Details | ||
| 11/10/2022 | BeiGene, Ltd. | BGNE | Maintain | Buy (N/A) |
|
Details | ||
| 10/13/2022 | BeiGene, Ltd. | BGNE | Upgrade | Buy (Neutral) |
151.30 (184.71) |
22.08% | Details | |
| 8/15/2022 | Seagen | SGEN | Maintain | Buy (N/A) |
|
Details | ||
| 6/13/2022 | Turning Point Therapeutics Inc. | TPTX | Downgrade | Neutral (Buy) |
74.47 (76.01) |
2.07% | Details | |
| 5/20/2022 | Mirati Therapeutics | MRTX | Upgrade | Buy (Neutral) |
59.61 (58.70) |
-1.53% | Details | |
| 5/5/2022 | Allogene | ALLO | Maintain | Buy (N/A) |
|
Details | ||
| 3/22/2022 | ORIC Pharamceuticals | ORIC | Downgrade | Neutral (Buy) |
6.68 (13.71) |
105.24% | Details | |
| 3/1/2022 | Turning Point Therapeutics Inc. | TPTX | Maintain | Buy (N/A) |
|
Details | ||
| 12/6/2021 | Adicet Bio Inc. | ACET | Maintain | Buy (N/A) |
|
Details | ||
| 11/11/2021 | Zentalis Pharmaceuticals | ZNTL | Maintain | Buy (N/A) |
|
Details | ||
| 8/24/2021 | Immuneering Corporation | IMRX | New Coverage | Buy (N/A) |
29.43 (5.33) |
-81.89% | Details | |
| 8/10/2021 | Imago Biosciences Inc | IMGO | New Coverage | Buy (N/A) |
22.99 (36.01) |
56.63% | Details | |
| 8/10/2021 | Erasca Inc | ERAS | New Coverage | Buy (N/A) |
21.15 (15.47) |
-26.86% | Details | |
| 5/18/2021 | Rain Therapeutics | RAIN | New Coverage | Buy (N/A) |
15.97 (2.80) |
-82.47% | Details | |
| 4/28/2021 | Cellectis | CLLS | Downgrade | Neutral (Buy) |
20.01 (3.56) |
-82.21% | Details | |
| 4/8/2021 | Adicet Bio Inc. | ACET | New Coverage | Buy (N/A) |
12.87 (7.29) |
-43.36% | Details | |
| 3/9/2021 | Five Prime Therapeutics | FPRX | Downgrade | Neutral (Buy) |
37.76 (38.00) |
0.64% | Details | |
| 3/2/2021 | Bolt Biotherapeutics, Inc. | BOLT | New Coverage | Buy (N/A) |
30.00 (4.30) |
-85.67% | Details | |
| 2/25/2021 | Agios Pharma | AGIO | Maintain | Buy (N/A) |
|
Details | ||
| 9/22/2020 | Five Prime Therapeutics | FPRX | Upgrade | Buy (Neutral) |
3.83 (38.00) |
892.17% | Details | |
| 9/15/2020 | Kymera Therapeutics | KYMR | New Coverage | Buy (N/A) |
32.78 (61.44) |
87.43% | Details | |
| 9/14/2020 | Seattle Genetics | SGEN | Maintain | Buy (N/A) |
|
Details | ||
| 8/6/2020 | Xencor, Inc. | XNCR | Maintain | Buy (N/A) |
|
Details | ||
| 8/6/2020 | Immunomedics | IMMU | Maintain | Buy (N/A) |
|
Details | ||
| 7/7/2020 | Immunomedics | IMMU | Maintain | Buy (N/A) |
|
Details | ||
| 6/30/2020 | Seattle Genetics | SGEN | Maintain | Buy (N/A) |
|
Details | ||
| 6/15/2020 | Agios Pharma | AGIO | Maintain | Buy (N/A) |
|
Details | ||
| 6/10/2020 | Fate Therapeutics | FATE | Maintain | Buy (Buy) |
|
Details | ||
| 5/19/2020 | ORIC Pharamceuticals | ORIC | New Coverage | Buy (N/A) |
31.88 (13.71) |
-56.99% | Details | |
| 5/15/2020 | Allogene | ALLO | Upgrade | Buy (Neutral) |
42.12 (2.30) |
-94.54% | Details | |
| 5/1/2020 | Seattle Genetics | SGEN | Upgrade | Buy (Neutral) |
137.23 (228.74) |
66.68% | Details | |
| 4/28/2020 | Zentalis Pharmaceuticals | ZNTL | New Coverage | Buy (N/A) |
31.76 (2.30) |
-92.76% | Details | |
| 4/6/2020 | Immunomedics | IMMU | Maintain | Buy (N/A) |
|
Details | ||
| 3/13/2020 | Rubius | RUBY | Maintain | Buy (N/A) |
|
Details | ||
| 3/9/2020 | Revolution | RVMD | New Coverage | Buy () |
31.96 (98.40) |
207.88% | Details | |
| 2/25/2020 | Xencor, Inc. | XNCR | Upgrade | Buy (Neutral) |
33.32 (11.32) |
-66.03% | Details | |
| 2/18/2020 | Neoleukin Therapeutics | NLTX | New Coverage | Buy (N/A) |
11.06 (3.49) |
-68.44% | Details | |
| 1/6/2020 | Forty Seven Inc. | FTSV | Maintain | Buy (N/A) |
|
Details | ||
| 1/2/2020 | Turning Point Therapeutics Inc. | TPTX | Maintain | Buy (N/A) |
|
Details | ||
| 1/2/2020 | Seattle Genetics | SGEN | Downgrade | Neutral (Buy) |
114.26 (137.23) |
20.1% | Details | |
| 1/2/2020 | Incyte | INCY | Downgrade | Neutral (Buy) |
87.32 (95.94) |
9.87% | Details | |
| 12/26/2019 | Spectrum Pharmaceuticals | SPPI | Downgrade | Neutral (Buy) |
8.75 (1.03) |
-88.23% | Details | |
| 12/11/2019 | Forty Seven Inc. | FTSV | Maintain | Buy (N/A) |
|
Details | ||
| 12/2/2019 | Exelixis | EXEL | Maintain | Buy (N/A) |
|
Details | ||
| 11/25/2019 | Arvinas Inc. | ARVN | New Coverage | Buy (N/A) |
34.67 (13.60) |
-60.77% | Details | |
| 11/15/2019 | BeiGene, Ltd. | BGNE | Maintain | Buy (N/A) |
|
Details | ||
| 11/1/2019 | BeiGene, Ltd. | BGNE | Maintain | Buy (N/A) |
|
Details | ||
| 10/30/2019 | Cellectis | CLLS | Buy (N/A) |
11.14 (3.56) |
-68.04% | Details | ||
| 10/22/2019 | Seattle Genetics | SGEN | New Coverage | Buy (N/A) |
100.89 (228.74) |
126.72% | Details | |
| 10/15/2019 | Exelixis | EXEL | Maintain | Buy (N/A) |
|
Details | ||
| 10/14/2019 | IGM Biosciences | IGMS | New Coverage | Buy (N/A) |
17.25 (1.27) |
-92.64% | Details | |
| 10/1/2019 | Five Prime Therapeutics | FPRX | Downgrade | Neutral (Buy) |
4.28 (38.00) |
787.85% | Details | |
| 9/27/2019 | Incyte | INCY | Maintain | Buy (N/A) |
|
Details | ||
| 9/24/2019 | Mirati Therapeutics | MRTX | Upgrade | Buy (Neutral) |
89.63 (58.70) |
-34.51% | Details | |
| 9/23/2019 | Agios Pharma | AGIO | Upgrade | Buy (Neutral) |
36.31 (27.48) |
-24.32% | Details | |
| 8/22/2019 | BeiGene, Ltd. | BGNE | Maintain | Buy (N/A) |
|
Details | ||
| 8/13/2019 | Deciphera | DCPH | Maintain | Buy (N/A) |
|
Details | ||
| 8/8/2019 | Five Prime Therapeutics | FPRX | Maintain | Buy (N/A) |
|
Details | ||
| 8/7/2019 | Xencor, Inc. | XNCR | Downgrade | Neutral (Buy) |
46.27 (33.32) |
-27.99% | Details | |
| 8/2/2019 | Clovis Oncology | CLVS | Downgrade | Neutral (Buy) |
10.55 (0.08) |
-99.24% | Details | |
| 8/2/2019 | Adaptimmune Therapeutics plc | ADAP | Downgrade | Neutral (Buy) |
3.29 (0.05) |
-98.48% | Details | |
| 7/24/2019 | Turning Point Therapeutics Inc. | TPTX | New Coverage | Buy (N/A) |
39.50 (76.01) |
92.43% | Details | |
| 5/30/2019 | Array BioPharma | ARRY | Maintain | Buy (N/A) |
|
Details | ||
| 5/22/2019 | Array BioPharma | ARRY | Maintain | Buy (N/A) |
|
Details | ||
| 5/13/2019 | Spectrum Pharmaceuticals | SPPI | New Coverage | Buy (N/A) |
9.32 (8.75) |
-6.12% | Details | |
| 5/8/2019 | Array BioPharma | ARRY | Maintain | Buy (N/A) |
|
Details | ||
| 5/7/2019 | Array BioPharma | ARRY | Maintain | Buy (N/A) |
|
Details | ||
| 4/12/2019 | Merus N.V. | MRUS | New Coverage | Buy (N/A) |
13.56 (90.00) |
563.72% | Details | |
| 4/12/2019 | Five Prime Therapeutics | FPRX | New Coverage | Buy (N/A) |
13.05 (4.28) |
-67.2% | Details | |
| 4/12/2019 | Xencor, Inc. | XNCR | New Coverage | Buy (N/A) |
31.62 (46.27) |
46.33% | Details | |
| 4/12/2019 | MacroGenics | MGNX | New Coverage | Neutral (N/A) |
18.34 (8.67) |
-52.73% | Details | |
| 4/12/2019 | Forty Seven Inc. | FTSV | New Coverage | Buy (N/A) |
17.46 (93.91) |
437.86% | Details | |
| 3/4/2019 | Mirati Therapeutics | MRTX | Maintain | Buy (N/A) |
|
Details | ||
| 3/4/2019 | Immunogen Inc. | IMGN | Maintain | Buy (N/A) |
|
Details | ||
| 3/1/2019 | Immunogen Inc. | IMGN | Maintain | Buy (N/A) |
|
Details | ||
| 2/13/2019 | Exelixis | EXEL | Maintain | Buy (Buy) |
|
Details | ||
| 2/5/2019 | Array BioPharma | ARRY | Maintain | Buy (N/A) |
|
Details | ||
| 1/3/2019 | Puma Biotechnology | PBYI | Downgrade | Neutral (Buy) |
20.35 (6.05) |
-70.27% | Details | |
| 1/3/2019 | Incyte | INCY | Upgrade | Buy (Neutral) |
63.59 (95.94) |
50.87% | Details | |
| 12/4/2018 | Tesaro | TSRO | Downgrade | Neutral (Buy) |
46.38 (74.96) |
61.62% | Details | |
| 10/29/2018 | Mirati Therapeutics | MRTX | Upgrade | Buy (Neutral) |
33.76 (89.63) |
165.49% | Details | |
| 10/2/2018 | Seattle Genetics | SGEN | Maintain | Buy (N/A) |
|
Details | ||
| 9/18/2018 | Tesaro | TSRO | New Coverage | Buy (N/A) |
34.92 (46.38) |
32.82% | Details | |
| 9/18/2018 | Seattle Genetics | SGEN | New Coverage | Buy (N/A) |
78.16 (100.89) |
29.08% | Details | |
| 9/18/2018 | Puma Biotechnology | PBYI | New Coverage | Buy () |
47.00 (20.35) |
-56.7% | Details | |
| 9/18/2018 | Mirati Therapeutics | MRTX | New Coverage | Neutral (N/A) |
55.30 (33.76) |
-38.95% | Details | |
| 9/18/2018 | Loxo Oncology | LOXO | New Coverage | Neutral (N/A) |
164.00 (234.80) |
43.17% | Details | |
| 9/18/2018 | Incyte | INCY | New Coverage | Neutral (N/A) |
68.09 (63.59) |
-6.61% | Details | |
| 9/18/2018 | Immunomedics | IMMU | New Coverage | Buy (N/A) |
22.27 (87.86) |
294.52% | Details | |
| 9/18/2018 | Immunogen Inc. | IMGN | New Coverage | Buy () |
8.86 (3.15) |
-64.45% | Details | |
| 9/18/2018 | Deciphera | DCPH | New Coverage | Buy (N/A) |
35.50 (25.59) |
-27.92% | Details | |
| 9/18/2018 | Clovis Oncology | CLVS | New Coverage | Buy () |
31.77 (10.55) |
-66.79% | Details | |
| 9/18/2018 | Blueprint Medicines | BPMC | New Coverage | Buy (N/A) |
73.99 (129.46) |
74.97% | Details | |
| 9/18/2018 | bluebird bio | BLUE | New Coverage | Neutral (N/A) |
146.10 (4.97) |
-96.6% | Details | |
| 9/18/2018 | BeiGene, Ltd. | BGNE | New Coverage | Buy (N/A) |
161.68 (176.03) |
8.88% | Details | |
| 9/18/2018 | Array BioPharma | ARRY | New Coverage | Buy (N/A) |
13.85 (6.81) |
-50.83% | Details | |
| 9/18/2018 | Agios Pharma | AGIO | New Coverage | Neutral (N/A) |
73.44 (36.31) |
-50.56% | Details | |
| 9/18/2018 | Adaptimmune Therapeutics plc | ADAP | New Coverage | Buy (N/A) |
11.07 (3.29) |
-70.28% | Details | |
| 9/18/2018 | Exelixis | EXEL | New Coverage | Buy (N/A) |
16.97 (41.55) |
144.84% | Details |
